Zobrazeno 1 - 10
of 127
pro vyhledávání: '"Peter Flachenecker"'
Autor:
Emilio Russo, Paula Martinez Agredano, Peter Flachenecker, Charlotte Lawthom, Duncan Munro, Chandni Hindocha, Makarand Bagul, Eugen Trinka
Publikováno v:
Journal of Cannabis Research, Vol 6, Iss 1, Pp 1-13 (2024)
Abstract Background Use of cannabis-based products is becoming more frequent, and it is important that healthcare professionals are informed and confident about them when making evidence-based decisions about their use. This study aimed to gain an in
Externí odkaz:
https://doaj.org/article/d040ad7061ba4ecd818be674830d4cc2
Autor:
Niklas Frahm, David Ellenberger, Alexander Stahmann, Firas Fneish, Daniel Lüftenegger, Hans C. Salmen, Ksenija Schirduan, Tom P. A. Schaak, Peter Flachenecker, Christoph Kleinschnitz, Friedemann Paul, Dagmar Krefting, Uwe K. Zettl, Melanie Peters, Clemens Warnke
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 17 (2024)
Background: The spectrum of disease-modifying therapies (DMTs) for people with multiple sclerosis (PwMS) has expanded over years, but data on treatment strategies is largely lacking. DMT switches are common clinical practice. Objective: To compare sw
Externí odkaz:
https://doaj.org/article/c8eeaeea69924efc9284aba8da3cbdca
Autor:
Anna Chorschew, Firat Kesgin, Judith Bellmann-Strobl, Peter Flachenecker, Insa Schiffmann, Friederike Rosenthal, Patrick Althoff, Daniel Drebinger, Radina Arsenova, Ludwig Rasche, Eva-Maria Dorsch, Christoph Heesen, Friedemann Paul, Jan-Patrick Stellmann, Tanja Schmitz-Hübsch
Publikováno v:
Health and Quality of Life Outcomes, Vol 21, Iss 1, Pp 1-12 (2023)
Abstract Background Gait impairment is a relevant problem in persons with multiple sclerosis (pwMS). The Multiple Sclerosis Walking Scale 12 (MSWS-12) is a valid Patient Reported Outcome Measure (PROM) to evaluate walking ability in pwMS. The aim of
Externí odkaz:
https://doaj.org/article/f4ac443d2e3443d9b97e18b000f6669d
Autor:
Lisa-Marie Ohle, David Ellenberger, Peter Flachenecker, Tim Friede, Judith Haas, Kerstin Hellwig, Tina Parciak, Clemens Warnke, Friedemann Paul, Uwe K. Zettl, Alexander Stahmann
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Abstract In 2001, the German Multiple Sclerosis Society, facing lack of data, founded the German MS Registry (GMSR) as a long-term data repository for MS healthcare research. By the establishment of a network of participating neurological centres of
Externí odkaz:
https://doaj.org/article/3654845ac2f64275b780abb489f96ac1
Clinical Predictors of Neurogenic Lower Urinary Tract Dysfunction in Persons with Multiple Sclerosis
Autor:
Janina Beck, Anke Kirsten Jaekel, Federico Leopoldo Zeller, Michael Kowollik, Ines Kurze, Albert Kaufmann, Wolfgang Feneberg, Anna Brandt, Peter Flachenecker, Thomas Henze, Burkhard Domurath, Paul Schmidt, Will Nelson Vance, Franziska Goldschmidt, Ruth Klara Maria Kirschner-Hermanns, Stephanie C. Knüpfer
Publikováno v:
Diagnostics, Vol 12, Iss 1, p 191 (2022)
Background: Multiple sclerosis patients often develop neurogenic lower urinary tract dysfunction with a potential risk of upper urinary tract damage. Diagnostic tools are urodynamics, bladder diary, uroflowmetry, and post-void residual, but recommend
Externí odkaz:
https://doaj.org/article/44e7d28572974209a5a77343133418d9
Publikováno v:
Case Reports in Neurology, Vol 10, Iss 2, Pp 169-176 (2018)
Multiple sclerosis (MS) is an inflammatory and neurodegenerative autoimmune demyelinating disease of the central nervous system. Patients exhibit heterogeneous patterns of disabling symptoms, including spasticity. In the majority of patients with MS
Externí odkaz:
https://doaj.org/article/c5bf9d8277b147eeb32ea32abb67adbe
Autor:
Anke Stroet, Claudia Hemmelmann, Michaela Starck, Uwe Zettl, Jan Dörr, Friedemann Paul, Peter Flachenecker, Vinzenz Fleischer, Frauke Zipp, Holger Nückel, Bernd C Kieseier, Andreas Ziegler, Ralf Gold, Andrew Chan
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 5 (2012)
Background: The incidence of therapy-related acute leukaemia (TRAL) in mitoxantrone treatment in multiple sclerosis (MS) is controversially discussed. Methods and results: In a retrospective meta-analysis from six centres, we observed six cases of ac
Externí odkaz:
https://doaj.org/article/8709d2e62d4e4f8090bcca2c7e28a3a9
Autor:
Isabel Voigt, Christine Stadelmann, Sven G. Meuth, Bernhard Schipp, Peter Flachenecker, Mathias Mäurer, Richard H. W. Funk, Franziska Ramisch, Joachim Niemeier, Tjalf Ziemssen
Publikováno v:
Wiener Medizinische Wochenschrift. 172:383-391
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b0801b486dd389974620c44350f725f
https://doi.org/10.1007/s10354-021-00900-3
https://doi.org/10.1007/s10354-021-00900-3
Publikováno v:
Journal of Neurology
Background Fatigue is one of the most frequent symptoms in patients with multiple sclerosis (MS), causing a major impact on quality-of-life. Non-pharmacological intervention strategies involve physical activity, which has been shown to reduce fatigue
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::957eb2d34d40ee62eca8b4fc94e67b9e
http://europepmc.org/articles/PMC8563680
http://europepmc.org/articles/PMC8563680
Autor:
Ruth Kirschner-Hermanns, Anna Brandt, Burkhard Domurath, W Feneberg, Christoph Schäfer, Albert Kaufmann, Ines Kurze, Jörn Bremer, Manuela Vonthien, T Henze, Kerstin Ratering, Paul Schmidt, Peter Flachenecker, Will Nelson Vance
Publikováno v:
Der Nervenarzt. 92:349-358
Zusammenfassung Hintergrund In der Routine steht man vor der Aufgabe, neurogene Störungen des unteren Harntraktes (NLUTD) bei Patienten mit Multipler Sklerose (MS) frühzeitig zu erkennen und adäquat zu therapieren. Verschiedene nationale Leitlinie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8fd44b8b6097430daa8cd83394515520
https://doi.org/10.1007/s00115-020-01046-0
https://doi.org/10.1007/s00115-020-01046-0